Skip to main content

Table 1 Baseline characteristics of the endometrioma and/or endometriosis-related pain recurrence and nonrecurrence groups

From: Risk factors for postoperative recurrence of ovarian endometriosis: long-term follow-up of 358 women

Characteristics Recurrence group (n = 68) Nonrecurrence group (n = 290) χ2 p value
Age, y 31.8 ± 5.0 32.9 ± 5.2 1.457 0.146
Gravida 0 (0–4) 1 (0–10) 1.207 0.228
Parity 0 (0–1) 0 (0–2) 2.385 0.018
BMI, kg/m2 20.9 ± 2.5 21.2 ± 2.6 0.814 0.416
rAFS stage    3.093 0.377
 Stage I 0 (0%) 1 (0.3%)   
 Stage II 3 (4.4%) 7 (2.4%)   
 Stage III 20 (29.4%) 113 (39.2%)   
 Stage IV 45 (66.2%) 167 (58.0%)   
Largest-diameter endometrioma, cm
 Left 5.6 ± 1.9 5.4 ± 2.2 −0.707 0.481
 Right 5.7 ± 2.0 5.2 ± 1.8 −1.631 0.104
CA125, U/ml 99.23 ± 89.72 100.37 ± 228.61 0.038 0.970
Dysmenorrhea, VAS 7 (0–10) 5 (0–10) −3.018 0.003
Extent of dysmenorrhea    15.420 0.001
 None 4 (5.9%) 81 (27.9%)   
 Mild 10 (14.7%) 40 (13.8%)   
 Moderate 20 (29.4%) 58 (20.0%)   
 Severe 34 (50.0%) 111 (38.3%)   
Duration of dysmenorrhea, m 84 (0–360) 24 (0–348) −3.514 0.001
Endometrioma side    3.082 0.214
 Left 16 (23.5%) 95 (32.8%)   
 Right 20 (29.4%) 62 (21.4%)   
 Bilateral 32 (47.1%) 133 (45.9%)   
Obliteration of cul-de-sac    3.307 0.191
 Absent 13 (19.1%) 81 (27.9%)   
 Partial 18 (26.5%) 84 (29.0%)   
 Complete 37 (54.4%) 125 (43.1%)   
Leiomyoma 18 (26.5%) 46 (16.0%) 5.057 0.044 (0.044)
Deep infiltrating endometriosis 41 (63%) 149 (51.4%) 1.758 0.224
Adenomyosis 34 (50.0%) 108 (37.4%) 4.059 0.044 (0.044)
Postoperative dysmenorrhea relief 55 (87.3%) 8 (90.0%) 1.770 0.413
Infertility    2.408 0.300
 Primary 11 (16.2%) 32 (11.0%)   
 Secondary 6 (8.8%) 17 (5.9%)   
Operation    0.705 0.590
 Cystectomy 65 (95.6%) 21 (72%).   
 Salpingo-oophorectomy 3 (4.4%) 269 (92.8%)   
Postoperative pregnancy 24 (35.3%) 113 (39.0%) 0.611 0.894
Postoperative medication    11.066 0.026
 None 0 (0%) 12 (4.1%)   
 OCP 1 (1.5%) 11 (3.8%)   
 Mirena 1 (1.5%) 13 (4.5%)   
 GnRHa with LNG-IUD 9 (13.2%) 69 (23.8%)   
 GnRHa without LNG-IUD 57 (83.8%) 185 (63.8%)   
Duration of follow-up 83 (60–120) 85 (60–116) −0.459 0.646
  1. Abbreviations: BMI Body mass index, CA-125 Cancer antigen 125, cm centimeter, GnRHa Gonadotropin-releasing hormone agonist, LNG-IUD Levonorgestrel-releasing intrauterine device, m month, OCP Oral contraceptive pills, VAS Visual analogue score